Healthcare [ 13/13 ] | Drug Manufacturers - General [ 139/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 6, 24 | 4.71 Increased by +15.16% | 4.61 Increased by +2.17% |
| Oct 31, 23 | 4.96 Increased by +5.53% | 4.67 Increased by +6.21% |
| Aug 3, 23 | 5 Increased by +7.53% | 4.49 Increased by +11.36% |
| Apr 27, 23 | 3.98 Decreased by -6.35% | 3.85 Increased by +3.38% |
| Jan 31, 23 | 4.09 Decreased by -6.19% | 4.1 Decreased by -0.24% |
| Nov 3, 22 | 4.7 Increased by +0.64% | 4.44 Increased by +5.86% |
| Aug 4, 22 | 4.65 Increased by +6.16% | 4.4 Increased by +5.68% |
| Apr 27, 22 | 4.25 Increased by +14.86% | 4.09 Increased by +3.91% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 8.2 B Increased by +19.84% | 767 M Decreased by -52.54% | Increased by +9.36% Decreased by -60.4% |
| Sep 30, 23 | 6.9 B Increased by +3.77% | 1.73 B Decreased by -19.27% | Increased by +25.06% Decreased by -22.21% |
| Jun 30, 23 | 6.99 B Increased by +5.94% | 1.38 B Increased by +4.71% | Increased by +19.74% Decreased by -1.17% |
| Mar 31, 23 | 6.11 B Decreased by -2.13% | 2.84 B Increased by +92.48% | Increased by +46.54% Increased by +96.67% |
| Dec 31, 22 | 6.84 B Decreased by -0.1% | 1.62 B Decreased by -14.9% | Increased by +23.63% Decreased by -14.82% |
| Sep 30, 22 | 6.65 B Decreased by -0.81% | 2.14 B Increased by +13.75% | Increased by +32.22% Increased by +14.67% |
| Jun 30, 22 | 6.59 B Increased by +1.04% | 1.32 B Increased by +183.84% | Increased by +19.97% Increased by +180.91% |
| Mar 31, 22 | 6.24 B Increased by +5.71% | 1.48 B Decreased by -10.33% | Increased by +23.66% Decreased by -15.17% |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.